Abstract
Tyrosine kinase inhibitors (TKIs) are targeted treatments for various cancers. Skin toxicities are one of the most common nonhematological side-effects of TKIs. We report an imatinib mesylate (IM) induced hyperpigmented acne rosacea (AR) and sunitinib-induced palmar hyperkeratosis in the case with gastrointestinal stromal tumor. AR was arisen due to the discontinuation of IM. To the best of our knowledge, this kind of cutaneous side-effect with IM has not been documented previously.
MeSH terms
-
Angiogenesis Inhibitors / adverse effects
-
Antineoplastic Agents / adverse effects*
-
Benzamides
-
Biopsy
-
Gastrointestinal Stromal Tumors / drug therapy*
-
Gastrointestinal Stromal Tumors / enzymology
-
Gastrointestinal Stromal Tumors / pathology
-
Histamine Antagonists / therapeutic use
-
Humans
-
Hyperpigmentation / chemically induced
-
Hyperpigmentation / pathology
-
Imatinib Mesylate
-
Indoles / adverse effects
-
Intestinal Neoplasms / drug therapy*
-
Intestinal Neoplasms / enzymology
-
Intestinal Neoplasms / pathology
-
Keratoderma, Palmoplantar / chemically induced
-
Keratoderma, Palmoplantar / pathology
-
Liver Neoplasms / drug therapy
-
Liver Neoplasms / secondary
-
Male
-
Middle Aged
-
Piperazines / adverse effects*
-
Protein Kinase Inhibitors / adverse effects*
-
Protein-Tyrosine Kinases / antagonists & inhibitors
-
Protein-Tyrosine Kinases / metabolism
-
Pyrimidines / adverse effects*
-
Pyrroles / adverse effects
-
Rosacea / chemically induced*
-
Rosacea / drug therapy
-
Rosacea / pathology
-
Skin / drug effects*
-
Skin / pathology
-
Skin Pigmentation / drug effects
-
Sunitinib
-
Treatment Outcome
Substances
-
Angiogenesis Inhibitors
-
Antineoplastic Agents
-
Benzamides
-
Histamine Antagonists
-
Indoles
-
Piperazines
-
Protein Kinase Inhibitors
-
Pyrimidines
-
Pyrroles
-
Imatinib Mesylate
-
Protein-Tyrosine Kinases
-
Sunitinib